Preclinical evaluation and phase 1 study of the PI3Kα/δ inhibitor TQ-B3525 in Chinese patients with advanced cancers.
Zhi-Ming LiXiang LiSu LiRong TaoXin TianFan FengWenqi JiangHuaqing WangPublished in: Cancer (2024)
TQ-B3525 exhibited rapid absorption and a nearly proportional increase in exposure. Acceptable safety and promising efficacy support further investigation of TQ-B3525 (20 mg once daily) for R/R lymphoma.